---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000112"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:40:14.739809+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis reports $392M cash; on track for azenosertib monotherapy dose, ASCO data

## Summary
- Cash, cash equivalents and marketable securities of $392M as of March 31, 2023; runway into Q2 2025.
- R&D expenses $48.6M (up $2.5M YoY); G&A expenses $16.4M (up $4.6M YoY), with lease impairment charges.
- On track to disclose azenosertib monotherapy dose in 1H 2023; positive Phase 1b chemo combo data in ovarian cancer at ASCO June 5.
- Appointed Diana Hausman, M.D. to Board of Directors; Funda Meric-Bernstam, M.D. to Scientific Advisory Board.
- ZN-d5 interim data in AL amyloidosis expected 2H 2023; Phase 1/2 combo with azenosertib in AML preliminary data also 2H 2023.

## SEC filing metadata
- accession: 0001725160-23-000112
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000112/0001725160-23-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000112/zntl-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000112
- JSON: https://secwatch.observer/filing/0001725160-23-000112.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000112.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2023.
  - Period: quarter ended March 31, 2023
  - Result: reported results
  source text: On May 10, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023 and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000112/0001725160-23-000112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.